Angiotensin receptor blockers and risk of dementia: Cohort study in UK Clinical Practice Research Datalink

British Journal of Clinical Pharmacology

Volumn 79, Issue 2, 2015, Pages 337-350

  Goh, Kah L ^a   Bhaskaran, Krishnan ^b   Minassian, Caroline ^b   Evans, Stephen J W ^b   Smeeth, Liam ^b   Douglas, Ian J ^b  

^a KLG Drug Safety Ltd Walnut House   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

angiotensin receptor blockers; angiotensin converting enzyme inhibitors; dementia

Indexed keywords

ALCOHOL; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONSULTATION; CONTROLLED STUDY; DEMENTIA; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EXPOSURE; DRUG USE; FEMALE; FOLLOW UP; HAZARD RATIO; HEART FAILURE; HUMAN; HYPERTENSION; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; RISK REDUCTION; SMOKING; SOCIOECONOMICS; TREATMENT DURATION; UNITED KINGDOM; VERY ELDERLY; ADOLESCENT; COMPARATIVE STUDY; FACTUAL DATABASE; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; DATABASES, FACTUAL; DEMENTIA; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84943526600     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12511     Document Type: Article

References (49)

1. Alzheimer's Disease International. World Alzheimer Report [online] 2009 Available at http://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf (last accessed 7 July 2012).
2. Newman AB, Fitzpatrick AL, Lopez O, Jackson S, Lyketsos C, Jagust W, Ives D, Dekosky ST, Kuller LH,. Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J Am Geriatr Soc 2005; 53: 1101-1107.
3. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R,. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005; 65: 545-551.
4. Nash DT, Fillit H,. Cardiovascular disease risk factors and cognitive impairment. Am J Cardiol 2006; 97: 1262-1265.
5. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K,. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005; 64: 277-281.
6. Breteler MM, Claus JJ, Grobbee DE, Hofman A,. Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study. BMJ 1994; 308: 1604-1608.
7. Kehoe PG, Wilcock GK,. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol 2007; 6: 373-378.
8. Oba R, Igarashi A, Kamata M, Nagata K, Takano S, Nakagawa H,. The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid β-peptide. Eur J Neurosci 2005; 21: 733-740.
9. Hemming ML, Selkoe DJ,. Amyloid β-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 2005; 280: 37644-37650.
10. Takeda S, Sato N, Takeuchi D, Kurinami H, Shinohara M, Niisato K, Kano M, Ogihara T, Rakugi H, Morishita R,. Angiotensin receptor blocker prevented β-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension 2009; 54: 1345-1352.
11. Li N-C, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B,. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010; 340: b5465.
12. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM,. Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis 2011; 26: 699-708.
13. Anderson C, Teo K, Gao P, Arima H, Dans A, Unger T, Commerford P, Dyal L, Schumacher H, Pogue J, Paolasso E, Holwerda N, Chazova I, Binbrek A, Young J, Yusuf S, ONTARGET and TRANSCEND Investigators. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol 2011; 10: 43-53.
14. Garcia Rodriguez LA, Perez Gutthann S,. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45: 419-425.
15. Clinical Practice Research Datalink (CPRD): Medicines and Healthcare products Regulatory Agency; [updated 2012 ]. Available at http://www.cprd.com/home/ (last accessed 7 January 2014).
16. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA,. Statins and the risk of dementia. [Erratum appears in Lancet 2001 Feb 17;357(9255):562]. Lancet 2000; 356: 1627-1631.
17. Joint Formulary Committee. British National Formulary. [online]. London: BMJ Group and Pharmaceutical Press, 2012; Available at http://www.bnf.org (last accessed 8 August 2012).
18. Fitchett D,. Results of the ONTARGET and TRANSCEND studies: an update and discussion. Vasc Health Risk Manag 2009; 5: 21-29.
19. Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR, Yusuf S,. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112: 1339-1346.
20. Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH,. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ 2013; 346: f360.
21. Onulgbo MA,. Re: efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ 2013; 346: f360. [eLetter] [Internet]. Available at http://www.bmj.com/content/346/bmj.f360/rr/629350 (last accessed 1 February 2014).
22. de Oliveira JMF,. Shall we excessively reduce systemic or tissue angiotensin II levels?. BMJ 2013; 346: f360. [eLetter] [Internet]. Available at http://www.bmj.com/content/346/bmj.f360/rr/628907 (last accessed 1 February 2014).
23. McGuinness B, Todd S, Passmore AP, Bullock R,. Systematic review: blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. J Neurol Neurosurg Psychiatry 2008; 79: 4-5.
24. Sink KM, Leng X, Williamson J, Kritchevsky SB, Yaffe K, Kuller L, Yasar S, Atkinson H, Robbins M, Psaty B, Goff DC, Jr,. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Arch Intern Med 2009; 169: 1195-1202.
25. Savva GM, Stephan BC,. Epidemiological studies of the effect of stroke on incident dementia: a systematic review. Stroke 2010; 41: e41-46.
26. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A,. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press 2007; 16: 135-232.
27. Ramsay L, Williams B, Johnston G, MacGregor G, Poston L, Potter J, Poulter N, Russell G,. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13: 569-592.
28. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, Thom SM,. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004; 328: 634-640.
29. North of England Hypertension Guideline Development Group (UK). Essential hypertension: managing adult patients in primary care [Internet]. In: Nice Clinical Guidelines No. 18, Newcastle upon Tyne (UK): University of Newcastle upon Tyne, 2004.
30. Benigni A, Cassis P, Remuzzi G,. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med 2010; 2: 247-257.
31. Wright JW, Harding JW,. The brain RAS and Alzheimer's disease. Exp Neurol 2010; 223: 326-333.
32. Murray IV, Proza JF, Sohrabji F, Lawler JM,. Vascular and metabolic dysfunction in Alzheimer's disease: a review. Exp Biol Med (Maywood) 2011; 236: 772-782.
33. van der Flier WM, Scheltens P,. Epidemiology and risk factors of dementia. J Neurol Neurosurg Psychiatry 2005; 76: (Suppl. 5): v2-7.
34. Lõpez-Sendõn J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C,. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004; 25: 1454-1470.
35. Vandoros S,. Generic policies and the 'Generic Paradox'. Euro Observer 2008; 10: 7-8.
36. Department of Health. PPRS: the study into the extent of competition in the supply of branded medicines to the NHS. 2011. Available at http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/Browsable/DH-5026918 (last accessed 15 March 2014).
37. Sandoz. Summary of product characteristics-Losartan Potassium 25mg Film-coated Tablets Available at http://www.medicines.org.uk/emc/medicine/23772/SPC/Losartan+Potassium+25+mg+Film-coated+Tablets/ (last accessed 16 March 2004).
38. Zentiva. Summary of Product Characteristics-Losartan Potassium 25mg film-coated tablets Available at http://www.medicines.org.uk/emc/medicine/23772/SPC/Losartan+Potassium+25+mg+Film-coated+Tablets/ (last accessed 16 March 2014).
39. Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, Powers B, Samsa GP, Gray RN,. AHRQ Comparative Effectiveness Reviews. Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors (Aceis) and Angiotensin II Receptor Antagonists (Arbs) for Treating Essential Hypertension. Rockville, MD: Agency for Healthcare Research and Quality (US), 2007.
40. National Prescribing Centre, NHS. Angiotensin-II receptor antagonists: what is the evidence for their place in therapy? MeReC Bull 2010; 20: 1-8.
41. Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS,. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc 2013; 88: 1213-1221.
42. Richardson K, Schoen M, French B, Umscheid CA, Mitchell MD, Arnold SE, Heidenreich PA, Rader DJ, deGoma EM,. Statins and cognitive function: a systematic review. Ann Intern Med 2013; 159: 688-697.
43. Coley N, Andrieu S, Gardette V, Gillette-Guyonnet S, Sanz C, Vellas B, Grand A,. Dementia prevention: methodological explanations for inconsistent results. Epidemiol Rev 2008; 30: 35-66.
44. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J,. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163: 1069-1075.
45. Brayne C, Stephan BCM, Matthews FE,. A European perspective on population studies of dementia. Alzheimers Dement 2011; 7: 3-9.
46. Jellinger KA,. Clinicopathological analysis of dementia disorders in the elderly-an update. J Alzheimers Dis 2006; 9: (3 Suppl.): 61-70.
47. White IR, Carlin JB,. Bias and efficiency of multiple imputation compared with complete-case analysis for missing covariate values. Stat Med 2010; 29: 2920-2931.
48. Fogari R, Mugellini A, Zoppi A, Marasi G, Pasotti C, Poletti L, Rinaldi A, Preti P,. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol 2004; 59: 863-868.
49. Fogari R, Mugellini A, Zoppi A, Lazzari P, Destro M, Rinaldi A, Preti P,. Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens 2006; 20: 177-185.